These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 4332385)

  • 1. [Pathophysiology of neuromuscular transmission disturbances].
    Elmqvist D
    Nord Med; 1971 Dec; 86(48):1442. PubMed ID: 4332385
    [No Abstract]   [Full Text] [Related]  

  • 2. Quantal components of end-plate potentials in the myasthenic syndrome.
    Lambert EH; Elmqvist D
    Ann N Y Acad Sci; 1971 Sep; 183():183-99. PubMed ID: 4330759
    [No Abstract]   [Full Text] [Related]  

  • 3. Variability of neuromuscular transmission in myasthenia gravis.
    Mayer RF; Williams IR; Snyder DH
    Trans Am Neurol Assoc; 1973; 98():83-6. PubMed ID: 4361779
    [No Abstract]   [Full Text] [Related]  

  • 4. [On the impaired neuromuscular transmission in myasthenia gravis].
    Kruckenberg P; Pontzen W; Sandweg R; Bauer H
    Z Neurol; 1971; 200(2):158-73. PubMed ID: 4108119
    [No Abstract]   [Full Text] [Related]  

  • 5. [Pathophysiology of myasthenia gravis and the myasthenic syndrome].
    Struppler A; Ruprecht EO
    Anaesthesist; 1971 Jan; 20(1):29-35. PubMed ID: 4322997
    [No Abstract]   [Full Text] [Related]  

  • 6. The kinetics of transmitter release in myasthenia gravis. II. An electrophysiological analysis of the replenishment of transmitter stores.
    Bergmans J; Rosselle N; Verheyen G; Schellens L
    Electromyogr Clin Neurophysiol; 1973; 13(1):3-58. PubMed ID: 4353757
    [No Abstract]   [Full Text] [Related]  

  • 7. The kinetics of transmitter release in myasthenia gravis. I. An electrophysiological analysis of the storage of transmitter.
    Bergmans J; Rosselle N; Verheyen G; Schellens L
    Electromyogr Clin Neurophysiol; 1972; 12(5):443-88. PubMed ID: 4350884
    [No Abstract]   [Full Text] [Related]  

  • 8. Mechanisms of fatigue in normal intercostal muscle and muscle from patients with myasthenia gravis.
    Pagala M; Nandakumar NV; Venkatachari SA; Ravindran K; Amaladevi B; Namba T; Grob D
    Muscle Nerve; 1993 Sep; 16(9):911-21. PubMed ID: 8355722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pathogenesis and pathophysiology of myasthenia gravis--electrophysiological, ultrastructural and immunological aspects of neuromuscular junctions (author's transl)].
    Takamori M; Tsujihata M; Ide Y; Eguchi K; Mine M
    No To Shinkei; 1980 Sep; 32(9):891-908. PubMed ID: 6254548
    [No Abstract]   [Full Text] [Related]  

  • 10. The kinetics of transmitter release in myasthenia gravis. 3. An electrophysiological analysis of the release of transmitter.
    Bergmans J; Rosselle N; Verheyen G; Schellens L
    Electromyogr Clin Neurophysiol; 1973; 13(2):145-73. PubMed ID: 4354573
    [No Abstract]   [Full Text] [Related]  

  • 11. [Diseases of the motoric end plate including myasthenia gravis].
    Struppler A
    Wien Klin Wochenschr; 1967 Aug; 79(33):620-2. PubMed ID: 4298887
    [No Abstract]   [Full Text] [Related]  

  • 12. [Interpretation of end plate potentials (EPP) and miniature end plate potentials (MEPP) by means of the Linc-8-computer, demonstrated with in vitro recordings from intercostal muscle of a patient with myasthenia gravis].
    Kruckenberg P; Bauer H
    Pflugers Arch; 1969; 307(2):R106. PubMed ID: 5814753
    [No Abstract]   [Full Text] [Related]  

  • 13. Physiology of neuromuscular transmission.
    Roberts DV; Wilson A
    Physiotherapy; 1972 Aug; 58(8):277-9. PubMed ID: 4360596
    [No Abstract]   [Full Text] [Related]  

  • 14. Streptomycin-induced neuromuscular fatigue in myasthenia gravis.
    Hokkanen E; Toivakka E
    Ann Clin Res; 1969 Nov; 1(3):220-6. PubMed ID: 4313111
    [No Abstract]   [Full Text] [Related]  

  • 15. [Physiopathological problems posed by myasthenia gravis].
    Desmedt JE
    Actual Pharmacol (Paris); 1967; 20():201-16. PubMed ID: 4306209
    [No Abstract]   [Full Text] [Related]  

  • 16. Pathophysiology of myasthenia gravis.
    Hughes BW; Moro De Casillas ML; Kaminski HJ
    Semin Neurol; 2004 Mar; 24(1):21-30. PubMed ID: 15229789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Facilitatory effects of 4-aminopyridine on neuromuscular transmission in disease states.
    Kim YI; Goldner MM; Sanders DB
    Muscle Nerve; 1980; 3(2):112-9. PubMed ID: 6245355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of cyclic 3',5'-adenosine monophosphate in neuromuscular transmission.
    Takamori M; Ishii N; Mori M
    Arch Neurol; 1973 Dec; 29(6):420-4. PubMed ID: 4148497
    [No Abstract]   [Full Text] [Related]  

  • 19. Rapid improvement of myasthenia gravis after plasma exchange.
    Nielsen VK; Paulson OB; Rosenkvist J; Holsøe E; Lefvert AK
    Ann Neurol; 1982 Feb; 11(2):160-9. PubMed ID: 6280584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intercostal muscle biopsy studies in myasthenia gravis: clinical correlations and the direct effects of drugs and myasthenic serum.
    Sanders DB; Kim YI; Howard JF; Johns TR; Muller WH
    Ann N Y Acad Sci; 1981; 377():544-66. PubMed ID: 6280565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.